EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Selective agonism of liver and gut FXR prevents cholestasis and intestinal atrophy in parenterally fed neonatal pigs

Yanjun Jiang, Zhengfeng Fang, Gregory Guthrie, Barbara Stoll, Shaji Chacko, Sen Lin, Bolette Hartmann, Jens J Holst, Harry Dawson, Jose J Pastor, Ignacio R Ipharraguerre, Douglas G Burrin

Journal of Lipid Research · 2025

DOI: 10.1016/j.jlr.2025.100919 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2025. Verfasst von Yanjun Jiang und 11 weiteren Autor:innen. Beteiligte Einrichtung: USDA/ARS Children's Nutrition Research Center, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Baylor Coll…. Hauptthemen laut MEDLINE: Receptors, Cytoplasmic and Nuclear, Cholestasis, Liver, Intestines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aimed to investigate the relative efficacy of feeding different bile acids in preventing PNALD in neonatal pigs. Newborn pigs given total parenteral nutrition (TPN) combined with minimal enteral feeding of chenodeoxycholic acid (CDCA) or increasing doses of obeticholic acid (OCA) for 19 days. Enteral OCA (5 and 15 mg/kg), but not CDCA (30 mg/kg) reduced blood cholestasis markers compared to TPN controls and increased bile acids in the gallbladder and intestine. Major bile acids in the liver and distal intestine were CDCA, HCA, HDCA, and OCA, and their relative proportions were increased by the type of bile acid (CDCA or OCA) given enterally. High doses of OCA increased the total NR1H4-agonistic bile acid profile in the liver and intestine above 50% total bile acids. Both CDCA and OCA treatments suppressed hepatic CYP7A1 expression, but only OCA increased hepatobiliary transporters, ABCB11, ABCC4, and ABCB1. Plasma phytosterol levels were reduced and biliary levels were increased by CDCA and OCA and hepatic sterol transporters, abcg5/8, expression were increased by OCA. Both CDCA and OCA increased plasma FGF19 and OCA increased intestinal FGF19, FABP6, and SLC51A. Both CDCA and OCA increased intestinal mucosal growth, whereas CDCA increased the plasma GLP-2, GLP-1 and GIP. Enteral OCA prevented cholestasis and phytosterolemia by increased hepatic bile acid and sterol transport via induction of hepatobiliary transporter NR1H4 target genes and not by suppression of bile acid synthesis genes. We also showed an intestinal trophic action of OCA that demonstrates a dual clinical benefit of NR1H4 agonism in the prevention of PNALD in pigs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Cytoplasmic and NuclearCholestasisLiverIntestinesIntestinal MucosaParenteral NutritionAnimalsSwineAnimals, NewbornChenodeoxycholic AcidBile Acids and SaltsReceptor, Farnesoid X-Activated

Stichwörter der Autor:innen

FGF19FXRcholestasisparenteral nutrition-associated liver diseasephytosterols

Substanzen

Receptors, Cytoplasmic and NuclearChenodeoxycholic AcidBile Acids and SaltsReceptor, Farnesoid X-Activatedobeticholic acid

Autor:innen und Institutionen

  • USDA/ARS Children's Nutrition Research Center, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
  • Key Laboratory of Agricultural Product Processing and Nutrition Health (Co-construction by Ministry and Province), Ministry of Agriculture and Rural Affairs, College of Food Science, Sichuan Agricultural University, Ya'…
  • Key Laboratory of Urban Agriculture in South China, Sericultural & Agri-Food Research Institute Guangdong Academy of Agricultural Sciences, Guangzhou, China.
  • NovoNordisk Foundation Center for Basic Metabolic Research and Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • USDA-ARS, Beltsville Human Nutrition Research Center, Diet, Genomics & Immunology Laboratory, Beltsville, MD, USA.
  • Innovation Division, Lucta S.A., Parc de Recerca UAB, Edifici Eureka, Catalonia, Spain.

Förderung

  • NIDDK NIH HHS
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Agricultural Research Service
  • American Society for Parenteral and Enteral Nutrition

Zitieren

APA

Jiang, Y., Fang, Z., Guthrie, G., Stoll, B., Chacko, S., Lin, S., Hartmann, B., Holst, J. J., Dawson, H., Pastor, J. J., Ipharraguerre, I. R., & Burrin, D. G. (2025). Selective agonism of liver and gut FXR prevents cholestasis and intestinal atrophy in parenterally fed neonatal pigs. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2025.100919

Vancouver

Jiang Y, Fang Z, Guthrie G, Stoll B, Chacko S, Lin S, et al. Selective agonism of liver and gut FXR prevents cholestasis and intestinal atrophy in parenterally fed neonatal pigs. Journal of Lipid Research. 2025. doi:10.1016/j.jlr.2025.100919

BibTeX
@article{Jiang2025,
  author = {Jiang, Yanjun and Fang, Zhengfeng and Guthrie, Gregory and Stoll, Barbara and Chacko, Shaji and Lin, Sen and Hartmann, Bolette and Holst, Jens J and Dawson, Harry and Pastor, Jose J and Ipharraguerre, Ignacio R and Burrin, Douglas G},
  title = {Selective agonism of liver and gut FXR prevents cholestasis and intestinal atrophy in parenterally fed neonatal pigs},
  journal = {Journal of Lipid Research},
  year = {2025},
  doi = {10.1016/j.jlr.2025.100919}
}
Kostenlos starten →